Claris Lifesciences Limited (Claris) was the Holding Company of Claris Injectables Limited, a wholly-owned subsidiary dealing in Specialty Injectables business that was carved out in November 2014. Claris Injectables was sold to Baxter International Inc. in July 2017.

Since its inception in 1999, Claris worked towards creating a niche in a highly-regulated business. Over a history of 17 years, we created nearly a billion-dollar valuation, with establishing world-class integrated business model that helped garner several stringent international regulatory approvals, including US FDA, MHRA (UK), TGA (Australia), MCC (South Africa), ANVISA (Brasil), INVIMA (Colombia), and GCC FDCA.